An even greater anti-tumor effect was observed when treatment with BRAF-inhibitors was combined with: i) anti PD-L1 or anti PD-1 antibodies [69]; ii) the BCR/ABL tyrosin-kynase inhibitor Dasatinib [68]; iii) proteasome inhibitors like Bortezomib [76]. Here, CD274 is linked to neoplasm.